Early Trial Data Highlights Potential of Gene Therapy GNT0004 for Duchenne Muscular Dystrophy
Long-term follow-up data from an early-phase study of an AAV8-based gene therapy for DMD suggest the treatment was well-tolerated and provided sustained biochemical and functional benefits.
Interim results from the ongoing, international, all-in-one GNT-016-MDYF trial indicated that GNT0004 (Genethon), an investigational gene therapy designed to target skeletal and cardiac muscles, led to sustained reductions in creatine kinase (CK) levels and stabilization or improvement in functional outcomes among young boys with Duchenne muscular dystrophy (DMD).1
Data from Part 1 of the study, which included a dose-escalation phase, showed that patients receiving Dose 2 (3×10¹³ vg/kg) experienced a persistent 68% reduction in CK levels over 2 years, suggesting long-term stabilization of muscle integrity. Additionally, clinical measures such as the North Star Ambulatory Assessment (NSAA) and stride velocity (SV95C) demonstrated improvements compared with an external control group from a natural history study.
The trial enrolled 5 ambulatory boys with DMD, aged 6 to 10 years, who were on stable corticosteroid treatment. Three patients received Dose 2, which was ultimately selected for further evaluation in the pivotal phase 3 portion of the study. All told, muscle biopsies at week 8 showed that 53% of fibers expressed the therapeutic dystrophin variant (hMD1).
Clinically, at 1 year, patients treated with Dose 2 demonstrated a 4.7-point improvement on the NSAA scale and a 0.1 m/s increase in SV95C, indicating stabilization or enhancement of motor function compared with the expected decline seen in untreated patients. Notably, no serious adverse events were reported at this dose level, supporting its potential safety profile.
These results were recently presented by Fei Cao, medical program lead at Genethon, at the
Building on these early findings,
At 8 weeks post-treatment, microdystrophin expression was detected in up to 85% of muscle fibers (mean: 54%; range: 15%-85%) based on immunohistochemistry, alongside reconstitution of the dystrophin-associated protein complex. This expression was supported by the presence of vector genome copies within muscle fiber nuclei (mean: 1.2; range: 0.4-2.4). Notably, the dosing regimen used in this trial was lower than that of other gene therapy studies for DMD.
Presented by principal investigator Francesco Muntoni, MD, chair of pediatric neurology in the Developmental Neurosciences Department at the Queen Square Center for Neuromuscular Diseases, reductions in creatine phosphokinase (CPK) levels were also observed, with an average decrease of 74% (range: 50%-87%) by week 12. Given CPK’s role as a key biomarker of muscle damage, this decline suggests reduced disease-related muscle breakdown.
For 1 patient in cohort 2 with available 1-year follow-up data, treatment with GNT0004 led to functional gains, as reflected by NSAA scores and improvements in measures such as the 10-Meter Walk Test and ability to stand up. These findings further support the therapy’s potential to modify disease progression, with additional confirmation expected from the next phase of clinical trials.
REFERENCES
1. Fei Cao. GNT0004, Genethon’s AAV-based gene therapy for Duchenne muscular dystrophy: long-term data of boys enrolled in the phase I/II of GNT-016-MDYF study. Presented at: 2025 MDA Clinical & Scientific Conference; March 16-19. Dallas, TX. Abstract LB423.
2. First Clinical Trial Results of Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy presented at International Myology 2024 Congress. News release. Genethon. Published April 23, 2024. Accessed March 17, 2025. https://www.genethon.com/first-clinical-trial-results-of-gene-therapy-gnt0004-for-duchenne-muscular-dystrophy-presented-at-international-myology-2024-congress/
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025